Giant Cell Tumor

The FDA has approved two new biosimilars of denosumab to treat osteoporosis, increase bone mass, prevent skeletal-related events for people with multiple myeloma and other indications, Samsung Bioepis announced.

Vimseltinib improved objective response rate compared with placebo for patients with tenosynovial giant cell tumor, according to topline data from the agent’s manufacturer.

According to published results, use of a 0.05% chlorhexidine gluconate solution may serve as a chemical adjuvant to intralesional curettage for patients with chondrosarcomas and giant cell tumors.